Upstream Bio, Inc. (NASDAQ: UPB)

Sector: Healthcare Industry: Biotechnology CIK: 0002022626
P/B 3.84
P/E -11.84
P/S 519.41
Market Cap 1.45 Bn
ROIC (Qtr) -35.56
Div Yield % 0.00
Rev 1y % (Qtr) 12.52
Total Debt (Qtr) 1.42 Mn
Debt/Equity (Qtr) 0.00

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 72.36M provide 101.06x coverage of short-term debt 716000, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 391.19M provides 275.68x coverage of total debt 1.42M, indicating robust asset backing and low credit risk.
  • Short-term investments of 300.26M provide solid 41.47x coverage of other current liabilities 7.24M, indicating strong liquidity.
  • Tangible assets of 391.19M provide robust 54.03x coverage of other current liabilities 7.24M, indicating strong asset backing.
  • Cash reserves of 72.36M provide robust 6.08x coverage of current liabilities 11.91M, indicating strong short-term solvency.

Cons

  • Investment activities of (110.51M) provide weak support for R&D spending of 118.41M, which is -0.93x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Short-term investments of 300.26M significantly exceed cash reserves of 72.36M, which is 4.15x, indicating potentially excessive yield-seeking behavior at the expense of liquidity.
  • The company's operating cash flow of (122.26M) shows concerning coverage of stock compensation expenses of 9.91M, with a -12.33 ratio indicating potential earnings quality issues.
  • Free cash flow of (122.55M) provides weak coverage of capital expenditures of 296000, with a -414.03 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (122.23M) show weak coverage of depreciation charges of 726000, with a -168.36 ratio indicating high capital intensity and potential reinvestment needs.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 3.60 12.31
EV to Cash from Ops. -11.53 23.25
EV to Debt 993.48 738.44
EV to EBIT -11.53 -9.16
EV to EBITDA -10.09 6.95
EV to Free Cash Flow [EV/FCF] -11.50 21.90
EV to Market Cap 0.97 65.67
EV to Revenue 503.66 227.32
Price to Book Value [P/B] 3.84 22.34
Price to Earnings [P/E] -11.84 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio -224.04 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 9.20 -27.13
Cash and Equivalents Growth (1y) % 118.33 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -128.90 -46.93
EBITDA Growth (1y) % -112.93 -1.68
EBIT Growth (1y) % -128.90 -56.45
EBT Growth (1y) % -128.90 -12.70
EPS Growth (1y) % 146.10 -28.31
FCF Growth (1y) % -118.86 -31.90
Gross Profit Growth (1y) % 26.82 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.01 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 6.08 3.85
Current Ratio 32.67 7.27
Debt to Equity Ratio 0.00 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % -4,340.80 -18,234.31
EBIT Margin % -4,366.77 -18,580.80
EBT Margin % -4,366.77 -19,488.74
Gross Margin % 100.00 -7.59
Net Profit Margin % -4,386.40 -19,439.22